免疫疗法
医学
地铁列车时刻表
癌症免疫疗法
免疫系统
癌症
生物信息学
免疫学
计算生物学
生物
计算机科学
内科学
操作系统
作者
Adrienne M. Rothschilds,Karl Dane Wittrup
标识
DOI:10.1016/j.it.2018.11.003
摘要
The temporal progression of response to infection and the order of events in the cancer–immune cycle indicate the existence of an endogenous temporal program for the immune system. A growing number of examples illustrate that choice of dose schedule can either eliminate or synergistically amplify the therapeutic benefit of immunotherapeutic agents. Treatment schedule design should take into account both duration and sequencing of combination immunotherapy agents. New biomarkers such as circulating tumor DNA and cell counts derived from the blood can help align preclinical and clinical immunological timescales for clinical translation. A plethora of new cancer immunotherapies are under clinical development individually and in combination for a wide variety of indications, but optimizing therapeutic outcomes will require precise consideration of timing in treatment schedule design. In this review, we summarize the current understanding of the temporal rhythms of the anticancer immune response. Lessons learned in preclinical and clinical studies begin to define a framework for incorporating duration and sequencing into immunotherapy. We also discuss key challenges and opportunities for translation of temporally programmed treatment schedules to the clinic, including alignment of immunological timescales in preclinical models and humans, and the use of current and emerging biomarkers. A plethora of new cancer immunotherapies are under clinical development individually and in combination for a wide variety of indications, but optimizing therapeutic outcomes will require precise consideration of timing in treatment schedule design. In this review, we summarize the current understanding of the temporal rhythms of the anticancer immune response. Lessons learned in preclinical and clinical studies begin to define a framework for incorporating duration and sequencing into immunotherapy. We also discuss key challenges and opportunities for translation of temporally programmed treatment schedules to the clinic, including alignment of immunological timescales in preclinical models and humans, and the use of current and emerging biomarkers. costimulatory receptor expressed on the surface of a variety of cell types including T cells, NK cells, and DCs. cells such as DCs that take up antigens and are subsequently involved in priming and costimulation of T cells. antibodies that have two different target specificities because they have a different variable region on each of their two arms. a class of immunotherapy involving antagonizing receptors that stop or weaken lymphocyte activity (e.g., PD-1 and CTLA-4). DNA released from tumor cells found systemically, often identified by known tumor mutations. a harmful condition where the body produces excess inflammation in response to immunotherapy. a checkpoint receptor expressed on regulatory T cells and activated CD8+ and CD4+ effector T cells that blocks T cell costimulation. period of time for which a particular treatment is administered. process by which cancer escapes the immune system through soluble factors that suppress immune cells or cancer cell surface receptors that prevent immune recognition. an inflammatory cytokine with many functions including enhancing antibody-mediated cell killing and proliferation of lymphocytes. Ratio in the blood of neutrophils to lymphocytes. checkpoint receptor expressed on the surface of T cells that inhibits T cell activation. type of immune cells that restrain activation of the immune system. order in which individual agents in combination therapies are administered. group of receptors exerting related costimulatory effects on either APCs or T cells. Members of this family include 4-1BB (also known as CD137), OX40, CD40, and CD30. inflammatory cytokines such as IFNα with many functions including activation and maturation of APCs.
科研通智能强力驱动
Strongly Powered by AbleSci AI